期刊
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
卷 106, 期 7, 页码 -出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/dju146
关键词
-
类别
资金
- National Institutes of Health/National Cancer Institute [CA129080, CA165807]
- National Institutes of Health/National Heart, Lung, and Blood Institute [HL109054]
- Ovarian Cancer Research Fund
- Tell Every Amazing Lady, Louisa M. McGregor Ovarian Cancer Foundation [POE/JHU/01.12]
The chromatin remodeling gene, ARID1A, has been implied as a tumor suppressor, and its somatic inactivating mutations occur in a wide variety of human cancers, most frequently in ovarian and uterine endometrioid and ovarian clear cell carcinomas. Tumors with ARID1A mutations also frequently harbor PTEN or PIK3CA mutations, suggesting their collaboration in tumorigenesis. Here, we used a conditional knockout mouse model in which Arid1a and Pten were deleted either individually or in combination in the mouse ovarian surface epithelium. After 6 months, 59.1% of mice with Arid1a and Pten double knockout developed ovarian endometrioid or undifferentiated carcinoma, whereas the remaining mice showed hyperplasia of ovarian surface epithelium. In contrast, 52 mice with homozygous or heterozygous deletion in either Arid1a or Pten did not develop ovarian lesions. These results demonstrate that inactivation of Arid1a alone is insufficient for tumor initiation but it requires additional genetic alteration(s) such as Pten deletion to drive tumorigenesis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据